Truist reiterates Buy on Boston Scientific stock amid 2027 outlook

Truist Securities has reaffirmed its Buy rating and set a price target of $51.00 for Boston Scientific (NYSE:BSX) stock, despite the company facing challenges in 2027 due to a cyberattack in late August. The impact of the security breach on 2026-2027 results was greater than initially anticipated, leading to underperformance in sales and earnings per share growth for the coming year.

As a result, pipeline catalysts have now shifted to 2028, with electrophysiology, watchman devices, and China market risks not anticipated to improve until 2028. Truist predicts a 5% growth for the remaining 75% of the portfolio, with total revenue growth potentially reaching 6-7% or higher in 2028. They consider the outlook as de-risked with the revised projections and expect the stock to outperform current low-$40 levels, with a second-half 2027-2028 acceleration becoming investable by mid-2027.

The current stock price is $42.13, just 6% above its 52-week low of $39.57, indicating a tough year with a 55% decline year-to-date. Boston Scientific reported weaker-than-expected third-quarter 2026 results, with adjusted earnings per share at $0.73 versus the $0.75 forecast, and revenue at $5.14 billion, slightly beating estimates.

The cybersecurity incident disrupted operations, causing a 300 basis point loss in organic growth, amounting to $150 million and $0.07 of adjusted EPS. Oppenheimer downgraded the stock to Perform from Outperform due to growth concerns, while RBC Capital reduced its price target to $52 from $70, and Mizuho lowered it to $50 from $55, citing reduced fiscal 2026 growth expectations.

Canaccord also cut its price target to $48 from $66, maintaining a Buy rating, pointing to product launch delays as a contributing factor.